The trial missed its primary endpoint, but makes unique contributions; many see it as further evidence that the treatment helps iron-deficient patients with heart failure.

Related Keywords

United Kingdom , United States , Philadelphia , Pennsylvania , Boston , Massachusetts , Minnesota , University Of Pennsylvania , Chicago , Illinois , London , City Of , American , Gregoryd Lewis , Vifor Pharma , Kiran Musunuru , Paul Kalra , Theresa Mcdonagh , Amgen , American Heart Association , School Of Cardiovascular Sciences , King College Hospital , Boehringer Ingelheim , American Heart Association Scientific Sessions , University Of Glasgow , Perelman School Of Medicine , Novartis , Pfizer , Astrazeneca , European Society Of Cardiology , Portsmouth Hospitals University , Scientific Sessions , Mass General Brigham , Perelman School , College Hospital , Cardiovascular Sciences , Rate Ratios , Usual Care , Minnesota Living , Heart Failure Questionnaire , European Society , Verve Therapeutics , American Regent , Heart Association Scientific Sessions , Breaking Science , Breakthrough Strategies , Randomized Trial , Intravenous Ferric Derisomaltose , Heart Failure , Reduced Ejection , Presented November , Iron Deficiency Anemia , Heart , Iron Replacement Therapy , Cardiovascular Imaging , Ardiac Imaging , V Imaging , Intravenous Iv , Intravenous , Tv , Hospitals , Ejection Fraction Ef , Eft Ventricular Ejection Fraction Lvef , Uk National Health Service , United Kingdom National Health Service , K Nhs , Dhs , National Health Service , Quality Of Life , Pol , Ealth Related Quality Of Life , Ealth Rela ,